Walgreens Boots Alliance Provides Summary Notice of Pending and Proposed Settlement of Shareholder Derivative Action
01 Mai 2024 - 11:30PM
Business Wire
Walgreens (Nasdaq: WBA):
UNITED STATES DISTRICT COURT NORTHERN
DISTRICT OF ILLINOIS EASTERN DIVISION
VLADIMIR GUSINSKY REVOCABLE TRUST,
Derivatively on Behalf of WALGREENS BOOTS ALLIANCE, INC.,
Plaintiff,
v.
STEFANO PESSINA, JOSE E. ALMEIDA, JANICE
M. BABIAK, DAVID J. BRAILER, WILLIAM C. FOOTE, GINGER L. GRAHAM,
JOHN A. LEDERER, DOMINIC MURPHY, LEONARD D. SCHAEFFER, NANCY M.
SCHLICHTING, and JAMES A. SKINNER,
Defendants,
and
WALGREENS BOOTS ALLIANCE, INC., a Delaware
Corporation,
Nominal Defendant.
Case No. 23-cv-15654
SUMMARY NOTICE
SUMMARY NOTICE OF PENDENCY AND PROPOSED
SETTLEMENT OF SHAREHOLDER DERIVATIVE
ACTION
TO: ALL PERSONS WHO OWNED SHARES OF THE COMMON STOCK OF
WALGREENS BOOTS ALLIANCE, INC. (“WALGREENS” OR THE “COMPANY”) AS OF
APRIL 10, 2024 (“WALGREENS SHAREHOLDERS”).
PLEASE READ THIS SUMMARY NOTICE CAREFULLY, YOUR RIGHTS WILL
BE AFFECTED BY PROCEEDINGS IN THE LITIGATION.
YOU ARE HEREBY NOTIFIED, pursuant to Rule 23.1 of the Federal
Rules of Civil Procedure and an Order of the United States District
Court for the Northern District of Illinois (the “Court”), of (i)
the pendency of the above-captioned shareholder derivative action
(the “Action”), which was brought on behalf of and for the benefit
of nominal defendant Walgreens; and (ii) a proposed settlement of
the Actions (the “Settlement”), subject to Court approval, on the
terms and conditions set forth in a Stipulation and Agreement of
Settlement (the “Stipulation”) filed with the Court and available
for review as indicated below. On June 18, 2024, at 8:50 a.m., a
hearing (the “Settlement Hearing”) will be held before the
Honorable Matthew F. Kennelly, at the U.S. District Court for the
Northern District of Illinois, 219 South Dearborn St., Chicago, IL
60604, to: (a) determine whether the Settlement should be approved
by the Court as fair, reasonable, and adequate; (b) determine
whether the Court should enter the Judgment dismissing the Action
with prejudice pursuant to the Stipulation; (c) determine whether
to approve the agreed-to amount of attorneys’ fees and expenses to
be paid to Plaintiff’s Counsel; (d) hear and determine any
objections to the Settlement or to the fee and service awards; and
(e) rule on such other matters as the Court may deem
appropriate.
This is a summary notice only. A more detailed Notice of
Pendency and Proposed Settlement of Shareholder Derivative Action
and of Settlement Hearing (the “Notice”) that provides additional
information concerning the Action, the terms of the proposed
Settlement, and Walgreens Shareholders’ legal rights with respect
to the proposed Settlement is being furnished to the Securities and
Exchange Commission. You may also obtain a copy of the Notice, as
well as a copy of the Stipulation, from Walgreens’s website,
http://investor.walgreensbootsalliance.com.
If you owned shares of Walgreens common stock as of April 10,
2024 and continue to own such shares through June 18, 2024 (the
date of the Settlement Hearing), you may, if you wish to do so,
comment to the Court on the proposed Settlement and/or the amount
of attorneys’ fees and service awards. Any objections to the
proposed Settlement and/or the attorneys’ fees and service awards
must be filed with the Court and delivered to counsel for Plaintiff
and Defendants such that they are received by no later than June 4,
2024, in accordance with the instructions set forth in the
Notice.
PLEASE DO NOT CONTACT THE COURT, THE CLERK’S OFFICE, OR
WALGREENS REGARDING THIS NOTICE OR THE PROPOSED SETTLEMENT.
All questions about this notice or the proposed Settlement
should be directed to the following counsel for Plaintiff:
Matthew T. Hurst, Esq. Heffner
Hurst
30 N. LaSalle St., Suite 1210
Chicago IL 60602
(312) 346-3466
mhurst@heffnerhurst.com
By Order of the Court
About Walgreens
Walgreens (www.walgreens.com) is included in the U.S. Retail
Pharmacy and U.S. Healthcare segments of Walgreens Boots Alliance,
Inc. (Nasdaq: WBA), an integrated healthcare, pharmacy and retail
leader. True to its purpose of “more joyful lives through better
health,” Walgreens has a more than 120-year heritage of caring for
communities and providing trusted pharmacy services, and today is
playing a greater role as an independent partner of choice offering
healthcare services that improve care, lower costs, and help
patients. Operating nearly 9,000 retail locations across the U.S.
and Puerto Rico, Walgreens is proud to serve nearly 9 million
customers and patients daily. The company’s pharmacists are playing
a more critical role in healthcare than ever before, providing a
wide range of pharmacy and healthcare services, including those
that drive equitable access to care for some of the nation’s most
underserved populations. Walgreens offers customers and patients a
true omnichannel experience, with fully integrated physical and
digital platforms designed to deliver high-quality products and
healthcare services. Within the U.S. Healthcare segment, Walgreens
portfolio also includes businesses in primary care,
multi-specialty, post-acute care, urgent care, specialty pharmacy
services, population health and provider enablement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240501103679/en/
Matthew T. Hurst, Esq. Heffner Hurst (312) 346-3466
mhurst@heffnerhurst.com
Walgreens Boots Alliance (NASDAQ:WBA)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Walgreens Boots Alliance (NASDAQ:WBA)
Historical Stock Chart
Von Jun 2023 bis Jun 2024